I agree that this site is using cookies. You can find further informations here.
X
Salutari, V.
50  results:
Search for persons X
?
1

43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizu..:

Trillsch, F. ; Okamoto, A. ; Kim, J-W....
ESMO Open.  9 (2024)  - p. 103550 , 2024
Link: https://doi.org/10.1016/..
 
?
2

84P Lack of diversity in clinical trials leading to Food an..:

Giudice, E. ; Sganga, S. ; Rapisarda, E....
ESMO Open.  9 (2024)  - p. 103544 , 2024
Link: https://doi.org/10.1016/..
 
?
3

28P Real-life efficacy and safety of cemiplimab in advanced..:

Tuninetti, V. ; Virano, E. ; Salutari, V....
ESMO Open.  9 (2024)  - p. 103528 , 2024
Link: https://doi.org/10.1016/..
 
?
4

MITO END-3: efficacy of avelumab immunotherapy according to..:

Pignata, S. ; Califano, D. ; Lorusso, D....
Annals of Oncology.  35 (2024)  7 - p. 667-676 , 2024
Link: https://doi.org/10.1016/..
 
?
5

60P Exploration of homologous recombination deficiency test..:

Camarda, F. ; Marino, I. ; Giacomini, F....
ESMO Open.  9 (2024)  - p. 103567 , 2024
Link: https://doi.org/10.1016/..
 
?
6

29P fT3/fT4 ratio, systemic inflammation and skeletal muscl..:

Tuninetti, V. ; Virano, E. ; Calvo, A....
ESMO Open.  9 (2024)  - p. 103529 , 2024
Link: https://doi.org/10.1016/..
 
?
7

174P Endocrine disruptors and life STILe in patients carryi..:

Fabi, A. ; Franco, A. ; Cordisco, E. Lucci...
ESMO Open.  8 (2023)  1 - p. 101451 , 2023
Link: https://doi.org/10.1016/..
 
?
8

42P Efficacy of maintenance with PARPi in advanced ovarian ..:

Marchetti, C. ; Fagotti, A. ; Cassani, C....
ESMO Open.  8 (2023)  1 - p. 100822 , 2023
Link: https://doi.org/10.1016/..
 
?
9

52P Real-world data of niraparib in platinum sensitive rela..:

Musacchio, L. ; Palluzzi, E. ; Lauria, R....
ESMO Open.  8 (2023)  1 - p. 100832 , 2023
Link: https://doi.org/10.1016/..
 
?
10

MO-0049 SBRT in ovary cancer patients progressing within PA..:

Macchia, G. ; Campitelli, M. ; Russo, D....
Radiotherapy and Oncology.  182 (2023)  - p. S16-S17 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Combining PARP inhibition and immune checkpoint blockade in..:

Musacchio, L. ; Cicala, C.M. ; Camarda, F....
ESMO Open.  7 (2022)  4 - p. 100536 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic muta..:

Chiusolo, P. ; Marchetti, C. ; Rossi, M....
Leukemia Research.  108 (2021)  - p. 106681.21 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Predictors of progression free survival, overall survival a..:

Roncolato, F.T. ; O'Connell, R.L. ; Joly, F....
Gynecologic Oncology.  156 (2020)  1 - p. 45-53 , 2020
Link: https://doi.org/10.1016/..
 
?
14

ENGOT-ov43/keylynk-001: A phase III, placebo- and active-co..:

Coleman, R.L. ; Fujiwara, K. ; Sehouli, J....
Gynecologic Oncology.  159 (2020)  - p. 89-90 , 2020
Link: https://doi.org/10.1016/..
 
?
15

Impact of bevacizumab containing first line chemotherapy on..:

Petrillo, M. ; Amadio, G. ; Salutari, V....
Gynecologic Oncology.  142 (2016)  2 - p. 231-236 , 2016
Link: https://doi.org/10.1016/..
 
1-15